All In Biotech

Drug Trial Radar · NCT06554847

Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis

A Multi-Centered, Randomized, Double-Blinded, Placebo-Controlled Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) When Used In Combination With Topical Corticosteroid Treatment (TCS) in Participants With Moderate to Severe Atopic Dermatitis.

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 417 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

417

Actual

Start

Sep 23, 2024

Primary completion

Oct 20, 2025

Study completion Aug 18, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of 611 when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis.

Conditions

  • Dermatitis, Atopic
  • Eczema, Atopic

Interventions

  • 611Drug

    subcutaneous injection

  • PlaceboDrug

    subcutaneous injection

  • Topical corticosteroidDrug

    Topical

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants achieving EASI-75 (≥75% reduction from Baseline in EASI score)Time frame: Baseline to Week 16
  2. Percentage of patients with an IGA score of 0 or 1 and a reduction ≥2-points from Baseline to Week 16.Time frame: Baseline to Week 16

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Shanghai Dermatology Hospital

    Shanghai, Shanghai Municipality, China

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

  • The First Affiliated Hospital of Ningbo University

    Ningbo, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.